ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
6
views
0
references
Top references
cited by
0
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
430
similar
All similar
Record
: found
Abstract
: not found
Book Chapter
: not found
Adverse Events with Biomedicines
Belatacept
other
Author(s):
Giuseppe Tridente
Publication date
(Online):
December 10 2013
Publisher:
Springer Milan
Read this book at
Publisher
Buy book
Review
Review book
Invite someone to review
Bookmark
Cite as...
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
ScienceOpen Research
Author and book information
Book Chapter
Publication date (Print):
2014
Publication date (Online):
December 10 2013
Pages
: 465-472
DOI:
10.1007/978-88-470-5313-7_44
SO-VID:
7075b41a-c050-4c21-a42b-dd21e904410f
History
Data availability:
Comments
Comment on this book
Sign in to comment
Book chapters
pp. 3
Introduction
pp. 15
Adverse Drug Events to Biomedicines
pp. 25
Systemic Syndromes with Biomedicines
pp. 51
Monoclonal Antibodies
pp. 65
Abciximab
pp. 71
Adalimumab
pp. 81
Alemtuzumab
pp. 97
Basiliximab
pp. 105
Belimumab
pp. 113
Bevacizumab
pp. 127
Brentuximab
pp. 135
Canakinumab
pp. 143
Catumaxomab
pp. 149
Certolizumab
pp. 159
Cetuximab
pp. 173
Daclizumab
pp. 183
Denosumab
pp. 193
Eculizumab
pp. 201
Edrecolomab
pp. 203
Efalizumab
pp. 211
Gemtuzumab
pp. 219
Golimumab
pp. 229
Ibritumomab
pp. 237
Infliximab
pp. 251
Ipilimumab
pp. 263
Muromonab
pp. 267
Natalizumab
pp. 277
Nimotuzumab
pp. 281
Ofatumumab
pp. 291
Omalizumab
pp. 301
Palivizumab
pp. 313
Panitumumab
pp. 327
Pertuzumab
pp. 335
Ranibizumab
pp. 351
Rituximab
pp. 369
Tocilizumab
pp. 383
Tositumomab
pp. 393
Trastuzumab
pp. 409
Ustekinumab
pp. 425
Fusion Proteins
pp. 429
Abatacept
pp. 445
Aflibercept
pp. 463
Alefacept
pp. 465
Belatacept
pp. 473
Etanercept
pp. 495
Rilonacept
pp. 503
Romiplostim
pp. 515
Cytokines
pp. 523
Interleukins
pp. 531
Denileukin-Diftitox
pp. 539
Anakinra
pp. 551
Interferons
pp. 563
Hemopoietic Stimulatory Factors
pp. 573
Myelopoietic Stimulatory Factors
pp. 579
Thrombopoietic Stimulatory Factor
pp. 583
Pluripotent Growth Factors
pp. 587
Epidermal Growth Factors
pp. 593
Biomedicines as Adverse Event Inducers
pp. 625
Conclusions and Perspectives
Similar content
430
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant rejection
Authors:
Ippoliti
Belatacept-based immunosuppression in a chagasic adult recipient of en bloc pediatric kidneys.
Authors:
Federico Cicora
,
Marta Paz
,
Fernando A Mos
…
Belatacept: a new era of immunosuppression
Authors:
E. El-Charabaty
,
AS Geara
,
C Ting
…
See all similar